News | June 01, 2009

Study Measures Femoral Access Site Complications among 18,165 Patients

June 1, 2009 - A new study shows about 2 percent of 18,165 patients undergoing cardiac catheterization had femoral vascular complications.

The study conducted by the Bad Berka Central Clinic, Department of Cardiology in Germany, appears in the June 12 issue of the International Journal of Cardiology (Volume 135, June 12, 2009, Issue 1, Pages 66-71).

The affected patients acquired femoral arterio-venous fistulas (AVF) and arterial pseudoaneurysms (PSA), for which patient- or procedure-related risk factors could be identified. Most of AVF and PSA could be managed conservatively or without any treatment, the overall mortality is low, researchers said.

The study was conducted because the incidence, risk factors and clinical outcome of femoral access complications are not well defined, although important for stratification and treatment.

A total of 18,165 consecutive patients undergoing cardiac catheterization were enrolled in the prospective registry. For the diagnosis of AVF and PSA a clinical examination was performed in every patient followed by a Duplex examination in case of clinical suspicion of AVF/PSA. The impact of the following risk factors was assessed: age, body mass index, puncture of left vs. right groin, gender, hypertension, sheath size, peripheral artery disease, coumadin therapy, glycoprotein IIb/IIIa-inhibitors, pretreatment with thrombolytics, and emergency procedures.

Within three years a total of 334 complications were found (1.8 percent). The incidence of AVF and PSA was 0.6 percent (n=107) and 1.2 percent (n=227), respectively. The following significant independent risk factors were identified: arterial hypertension (odds ratio [OR])=1.86, female gender (OR=1.65), and emergency procedures (OR=2.13). During follow-up (mean 48±10 months) only 11 percent of all AVF underwent operative repair due to symptoms. The study found PSA could be treated successfully either by manual compression, thrombin injection, or surgery. The overall mortality was 0.8 percent, the study found.

For more information: www.internationaljournalofcardiology.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now